ABCAM PLC/ADR (OTCMKTS:ABCZY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Thursday.
According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “
Separately, ValuEngine downgraded shares of ABCAM PLC/ADR from a “buy” rating to a “hold” rating in a report on Friday, December 21st.
Shares of ABCZY stock traded down $1.26 during mid-day trading on Thursday, hitting $15.32. 391 shares of the stock were exchanged, compared to its average volume of 850. ABCAM PLC/ADR has a 52-week low of $12.52 and a 52-week high of $20.29.
ABCAM PLC/ADR Company Profile
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers
Get a free copy of the Zacks research report on ABCAM PLC/ADR (ABCZY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com